[PDF] Top 20 Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients

... these patients and should have a strict follow up of these ...to treatment-experienced patients in general remains to be ...positive patients received only 24 weeks of Peg-IFN ... See full document

... alfa-2a therapy for HBeAg-negative chronic hepatitis B patients in ...HBe-negative patients were enrolled to receive the 48-week treatment of 180 ug peg-INF once ... See full document

... incarcerated patients received treatment in the past two years since 2013 while the community patients were treated from ...more experienced in treating chronic hepatitis C and ... See full document

... tolerable treatment is available for patients with HBeAg-negative chronic hepatitis ...B. Interferon alfa has antiviral and immu- nomodulatory effects that can induce ... See full document

... Criteria for exclusion included a coexisting seri- ous medical or psychiatric illness; immune globu- lin, interferon, or other immune- or cytokine-based therapies with possible activity against HBV disease ... See full document

... Forty-three patients with chronic HCV ongoing interferon-alpha therapy were assessed with the Mini-International Neuropsychiatric Interview (MINI) for major depressive episodes ... See full document

... combination therapy with LdT plus PegIFN compared with either agent alone in patients with CHB in this trial must be certainly tempered by the early termination and small sample ...combination ... See full document

... factor for cirrhosis and hepatocellular carcinoma, even if the patients had low serum HBV DNA ...of patients and the number of patients lost to follow- up are limitations of this ...point ... See full document

... of patients were less than 60 years ...infected patients in the elderly population needs further ...procedure for diagnosis of TB infection (acid-fast stain, culturing and histopath- ...medication ... See full document

... compensate for RBV-induced hemolysis 12 ...criteria for HCV therapy has been loosened since November 2009 in ...more patients eligible for free treatment of ...the ... See full document

... Enrolled patients received lamivudine 100 mg, entecavir ...Insurance. For those who acquired on-treatment virological breakthrough, adefovir at a daily dose of 10mg was ...All patients were ... See full document

... and treatment responses, to examine the association of severe anemia and treatment responses, and to construct a clinically practical predictive index for severe anemia during HCV combination ... See full document

... Malcangi, and G. Pastore, Azienda Ospedaliera Consorziale Policlinico, Bari, Italy; G. Papatheodoridis and V. Sevastianos, Henry Dunant Hospital, Athens; K. Kaita and G. Y. Minuk, University of Manitoba Health Sciences ... See full document

... in Chronic Hepatitis B Patients Undergoing Entecavir Therapy Hsueh-Chou Lai, Cheng-Yuan Peng, Wen-Pang Su, Chia-Hsin Lin, Po-Heng Chuang, Jung-Ta Kao, Sheng-Hung Chen Division of ... See full document

... problem. For stability, the pole radius in the single notch filter design is specified by the designer, and in the multiple notch filter design, the pole radius is constrained by using the implica- tions of ... See full document

... the patients who lost HBeAg during their first year of lamivudine therapy showed a significantly higher rate of sustained remission off lamivudine therapy than those who did not lose HBeAg during the ... See full document

... the patients had chronic HBV infection, but the incidence of severe hepatitis was found to be 53%, which was associated with a mortality rate of ...in patients with haematological malignancies ... See full document

... judgement for scoring, was not incorporated into our study because the inter-observer variability could be considerable, especially in the absence of prospectively standardized appraisement 25 ...underlying ... See full document

... 60 chronic hepatitis B virus infection increases the risk of end-stage renal disease among. 11[r] ... See full document

... Eligible patients also had detectable HBsAg for at least 24 weeks before screening, evidence of chronic hepatitis on a baseline liver- biopsy specimen obtained within 52 weeks be- fore ... See full document